Jenphar Bangladesh Limited has achieved a remarkable milestone by registering its groundbreaking oncology product Olaparib INN Tablet (Juparib 100 mg & 150 mg) in Sri Lanka.
With its recent registration approval, Olaparib INN tablet is set to revolutionize cancer treatment and bring newfound hope to cancer patients across Sri Lanka. This momentous milestone reaffirms Jenphar Bangladesh’s commitment to advancing oncology care and providing cutting-edge solutions to create a new hope to cancer patients worldwide. Jenphar Bangladesh Limited is proud to contribute to the healthcare landscape in Sri Lanka and remains committed to enhancing patient care and fighting against cancer throughout the world.